keyword
MENU ▼
Read by QxMD icon Read
search

Drug eluting balloons

keyword
https://www.readbyqxmd.com/read/29439299/recurrent-in-stent-restenosis-in-the-area-of-previous-stent-fracture-a-management-dilemma
#1
Udit Bhaskar Bhatnagar, Josh Rezkalla, Tomasz Stys, Adam Stys
Drug eluting stents (DES) have been increasingly being used for treatment of coronary artery disease (CAD) and have been shown to be very effective in prevention of primary in-stent restenosis (ISR). However DES have been increasingly associated with acute to subacute risk of stent fractures (SF). There is also a paucity of data about different management strategies for SF, especially in the long term. We present a case of recurrent ISR in an area of previous acute SF at the touchdown of saphenous venous graft (SVG) to first diagonal artery (D1)...
January 2018: South Dakota Medicine: the Journal of the South Dakota State Medical Association
https://www.readbyqxmd.com/read/29435779/therapeutic-options-for-in-stent-restenosis
#2
REVIEW
Charles Nicolais, Vladimir Lakhter, Hafeez Ul Hassan Virk, Partha Sardar, Chirag Bavishi, Brian O'Murchu, Saurav Chatterjee
PURPOSE OF REVIEW: In-stent restenosis (ISR) is a complex disease process that became apparent shortly after the introduction of stents into clinical practice. This review seeks to define in-stent restenosis (ISR) as well as to summarize the major treatment options that have been developed and studied over the past two decades. RECENT FINDINGS: Recent developments in drug-coated balloons and bioresorbable vascular scaffolds have added new potential treatments for ISR...
February 12, 2018: Current Cardiology Reports
https://www.readbyqxmd.com/read/29413242/a-randomized-comparison-of-paclitaxel-eluting-balloon-versus-everolimus-eluting-stent-for-the-treatment-of-any-in-stent-restenosis-the-dare-trial
#3
Jan Baan, Bimmer E Claessen, Kirsten Boerlage-van Dijk, Jeroen Vendrik, René J van der Schaaf, Martijn Meuwissen, Niels van Royen, A T Marcel Gosselink, Marleen H van Wely, Atilla Dirkali, E Karin Arkenbout, Robbert J de Winter, Karel T Koch, Krischan D Sjauw, Marcel A Beijk, M Marije Vis, Joanna J Wykrzykowska, Jan J Piek, Jan G P Tijssen, José P S Henriques
OBJECTIVES: The authors sought to evaluate the relative performance of a drug-eluting balloon (DEB) and a drug-eluting stent (DES) in patients with any (bare-metal or drug-eluting stent) in-stent restenosis (ISR). BACKGROUND: The treatment of ISR remains challenging in contemporary clinical practice. METHODS: In a multicenter randomized noninferiority trial, patients with any ISR were randomly allocated in a 1:1 fashion to treatment with a DEB (SeQuent Please paclitaxel-eluting balloon, B...
February 12, 2018: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/29407132/comparison-of-mid-term-clinical-outcomes-after-treatment-of-ostial-right-coronary-artery-lesions-with-early-and-new-generation-drug-eluting-stents-insights-from-an-international-multicenter-registry
#4
Satoru Mitomo, Richard J Jabbour, Yusuke Watanabe, Antonio Mangieri, Marco Ancona, Damiano Regazzoli, Akihito Tanaka, Akihiro Nakajima, Toru Naganuma, Francesco Giannini, Azeem Latib, Sunao Nakamura, Antonio Colombo
BACKGROUND: There are only a limited number of studies comparing clinical outcomes after treatment of right coronary artery (RCA) aorto-ostial (AO) lesions with early (E-) and new (N-) generation drug-eluting stents (DES). METHODS: From January 2005 to December 2013, 334 de novo RCA AO lesions treated with DES (E-:142 lesions, N-:192 lesions) at 2 high-volume centers (Italy and Japan) were included in this study. The primary endpoint was target lesion failure (TLF) defined as composite of cardiac mortality, target vessel myocardial infarction, and target lesion revascularization (TLR)...
March 1, 2018: International Journal of Cardiology
https://www.readbyqxmd.com/read/29381087/the-evolution-of-coronary-stents
#5
Peter McKavanagh, George Zawadowski, Naveed Ahmed, Michael Kutryk
Percutaneous coronary intervention (PCI) is 40 years old this year. From its humble beginnings of experimental work, PCI has transitioned over years with coronary artery stenting now a standard medical procedure performed throughout the world. Areas covered: The conversion from plain old balloon angioplasty (POBA) to the present era of drug eluting stents (DES) has been driven by many technological advances and large bodies of clinical trial evidence. The journey to present day practice has seen many setbacks, such as acute vessel closure with POBA; rates of instant restenosis with bare metal stents (BMS) and more recently, high rates of stent thrombosis with bioabsorbable platforms...
January 30, 2018: Expert Review of Cardiovascular Therapy
https://www.readbyqxmd.com/read/29377941/sex-differences-in-the-outcomes-of-stent-implantation-in-mini-swine-model
#6
Mie Kunio, Gee Wong, Peter M Markham, Elazer R Edelman
Sex-related differences have been noted in cardiovascular anatomy, pathophysiology, and treatment responses, yet we continued to drive evaluation of vascular device development in animal models without consideration of animal sex. We aimed to understand sex-related differences in the vascular responses to stent implantation by analyzing the pooled data of endovascular interventions in 164 Yucatan mini-swine (87 female, 77 male). Bare metal stents (BMS) or drug-eluting stents (DES) were implanted in 212 coronary arteries (63 single BMS implantation, 68 single DES implantation, 33 overlapped BMS implantation, and 48 overlapped DES implantation)...
2018: PloS One
https://www.readbyqxmd.com/read/29374935/-therapeutic-efficacy-of-paclitaxel-coated-balloon-for-de-novo-coronary-lesions-with-diameters-larger-than-2-8-mm
#7
X Yu, F S Ji, F Xu, W D Zhang, X Y Wang, D Lu, T Xu
Objective: To evaluate the efficacy of paclitaxel-coated balloon for de novo coronary lesions with diameters ≥ 2.8 mm. Methods: This prospective study included 215 consecutive patients with 238 de novo lesions, who received paclitaxel-coated balloon angioplasty in Beijing Hospital from May 2014 to June 2016. According to the reference vessel diameter, the patients were divided into large vessel disease (LVD) group (reference vessel diameter≥2.8 mm, 85 patients and 90 lesions) and small vessel disease (SVD) group (reference vessel diameter<2...
January 24, 2018: Zhonghua Xin Xue Guan Bing za Zhi
https://www.readbyqxmd.com/read/29356269/bioresorbable-vascular-scaffold-versus-everolimus-eluting-stents-or-drug-eluting-balloon-for-the-treatment-of-coronary-in-stent-restenosis-1-year-follow-up-of-a-propensity-score-matching-comparison-the-bioresolve-isr-study
#8
Elisabetta Moscarella, Akihito Tanaka, Alfonso Ielasi, Bernardo Cortese, Sebastian Coscarelli, Maria Carmen De Angelis, Davide Piraino, Azeem Latib, Giulietta Grigis, Renatomaria Bianchi, Dario Buccheri, Paolo Calabrò, Maurizio Tespili, Pedro Silva Orrego, Antonio Colombo, Attilio Varricchio
OBJECTIVES: to compare the 1-year outcome between bioresorbable vascular scaffold (BVS), everolimus-eluting stent (EES), and drug-eluting balloon (DEB) for in-stent restenosis (ISR) treatment. BACKGROUND: BVS has been proposed as alternative for ISR treatment. To date a direct comparison between BVS and DES or DEB for ISR treatment is lacking. METHODS: We retrospectively analyzed all ISR lesions treated with BVS, DEB, and EES from January 2012 to December 2014...
January 22, 2018: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/29332315/comparison-of-treatment-strategies-for-femoro-popliteal-disease-a-network-meta-analysis
#9
Edward Koifman, Michael J Lipinski, Kyle Buchanan, Won Yu Kang, Ricardo O Escarcega, Ron Waksman, Nelson L Bernardo
OBJECTIVES: We sought to compare treatment strategies in a Bayesian network meta-analysis of randomized controlled trials. BACKGROUND: Peripheral artery disease (PAD) is a prevalent morbidity that is treated with various strategies. METHODS: We performed a MEDLINE search for randomized studies comparing at least 2 treatment strategies, including bypass surgery, percutaneous transluminal angioplasty (PTA) balloons, stents, covered stents, drug-eluting stents (DES), and drug-coated balloons (DCB), in patients with native femoro-popliteal disease...
January 14, 2018: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/29327573/treating-complex-femoro-popliteal-lesions
#10
Rozemarijn J van der Vijver-Coppen, Yannick W 't Mannetje, Theo P Menting, Jan-Willem Lardenoije, Michel M Reijnen
Peripheral artery disease affects 202 million patients worldwide and may cause disabling intermittent claudication and critical limb ischemia. Next to life style changes, best medical treatment and supervised exercise therapy, it can be necessary to re-vascularise the limb. Treatment of femoro-popliteal lesions poses a challenge and a surgical bypass remains recommended in the guidelines for longer and more complex lesions. Bypass surgery is associated with substantial morbidity and even mortality. Endovascular alternatives are quickly evolving from plain balloon angioplasty to drug-eluting stents, drug-coated balloons, polytetrafluoroethylene covered stents and atherectomy...
January 9, 2018: Journal of Cardiovascular Surgery
https://www.readbyqxmd.com/read/29283054/drug-coated-balloons-applications-in-interventional-cardiology
#11
Gianluca Rigatelli, Marco Zuin
BACKGROUNDS: Drug coated balloons (DCBs) are new on stented-based anti-proliferative drug delivery systems, recently introduced in interventional cardiology. Their primary aim is to transfer an anti-proliferative drug to reduce the subsequent neo-intima hyperplasia and to maintain the normal vessel diameter and function. METHODS: A review of the most recent influential studies about DCBs in all the fields of interventional cardiology has been performed. RESULTS: As demonstrated by different studies, DCBs have different theoretical advantages over drug eluting stents (DESs), especially for the treatment of some endovascular lesions, as in-stent restenosis (ISR), coronary bifurcations, small vessels disease and peripheral artery disease at femoropopliteal and below the knee sites...
December 27, 2017: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/29278215/percutaneous-coronary-intervention-in-the-elderly-are-drug-coated-balloons-the-future
#12
Ioannis Merinopoulos, Tharusha Gunawardena, Upul Wickramarachchi, Alisdair Ryding, Simon Eccleshall, Vassilios S Vassiliou
Balloon angioplasty revolutionised percutaneous treatment for coronary artery disease four decades ago, but vessel-threatening dissections, elastic recoil and restenosis were major drawbacks to an otherwise successful long-lasting intervention. Subsequent advances with bare metal stents and then drug eluting stents followed, aiming to mitigate the risks of acute vessel closure and restenosis. However, stent implantation often necessitates dual antiplatelet therapy for a prolonged period of time, which in itself can lead to adverse outcomes, especially in the frail elderly population at higher risk of bleeding...
December 26, 2017: Current Cardiology Reviews
https://www.readbyqxmd.com/read/29250834/comparison-of-drug-eluting-balloon-angioplasty-to-infrapopliteal-artery-critical-lesions-with-or-without-additional-pedal-artery-angioplasty-in-patients-with-diabetes-mellitus-and-critical-limb-ischemia
#13
Burak Teymen, Süleyman Aktürk
BACKGROUND: The purpose of this study is to investigate the feasibility and outcome of balloon angioplasty for the treatment of below the ankle (BTA) lesions in addition to below the knee (BTK) lesions in diabetic patients with critical limb ischemia (CLI). METHODS: Inclusion criteria are diabetes mellitus (DM), CLI (Rutherford class 4 or higher) and revascularized significant stenosis or occlusion of at least 1 below-the-knee vessel with incomplete or no pedal loop...
December 17, 2017: Journal of Interventional Cardiology
https://www.readbyqxmd.com/read/29248121/percutaneous-drug-eluting-balloon-angioplasty-to-treat-dialysis-access-stenosis
#14
Mafalda Massara, Pietro Finocchiaro, Alberto Volpe, Antonino Alberti, Pietro Volpe
A common complication of arteriovenous fistula for hemodialysis is development of conduit stenosis, which compromises function and can result in access thrombosis. Possible treatment options include open repair and endovascular therapy, with the latter preferred due to lower morbidity and similar outcomes. Recurrence of conduit stenosis is common and, based on the pathophysiology of this lesion, the application of drug-coated balloon angioplasty is attractive. In this report, the application of drug-eluting balloon angioplasty for dialysis access stenosis in 18 consecutive patients is detailed and primary patency rates of 82% at 1 year and 68% at 2 years were calculated...
June 2017: Seminars in Vascular Surgery
https://www.readbyqxmd.com/read/29247157/a-case-of-subacute-bioresorbable-vascular-scaffold-thrombosis-what-was-wrong
#15
Seraj A Abualnaja, Hanan M Alrammah, Bayan A Alsaif, Malak O Almulla, Bayan A Alzahrani
BACKGROUND The introduction of bioresorbable vascular scaffolds (BVS) into the field of percutaneous coronary intervention (PCI) was thought to be a promising step in solving the issues raised with the use of early bare metal stents (BMS) and drug eluting stents (DES); however, studies have raised concerns regarding thrombosis risk associated with the use of these stents. CASE REPORT A 42-year-old male presented with acute coronary syndrome (ACS), on diagnostic coronary angiography he had 75% and 70% stenosis in mid and distal left anterior descending artery (LAD) respectively, PCI with BVS implantation was done...
December 16, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/29230546/management-and-predictors-of-outcome-in-unselected-patients-with-cardiogenic-shock-complicating-acute-st-segment-elevation-myocardial-infarction-results-from-the-bremen-stemi-registry
#16
Tina Backhaus, Andreas Fach, Johannes Schmucker, Eduard Fiehn, Daniela Garstka, Janina Stehmeier, Rainer Hambrecht, Harm Wienbergen
INTRODUCTION: Patients with ST-segment elevation myocardial infarction (STEMI) and consecutive cardiogenic shock (CS) represent a challenge in clinical practice. Only few 'real-world' data on therapeutic management and outcome exist. METHODS: The present analysis focuses on changes of clinical management of STEMI-patients with CS and analyzes predictors of outcome using the Bremen-STEMI registry. RESULTS: Out of 7865 patients with STEMI, 981 patients (13%) presented with CS...
December 11, 2017: Clinical Research in Cardiology: Official Journal of the German Cardiac Society
https://www.readbyqxmd.com/read/29227279/drug-eluting-balloon-design-technology-and-clinical-aspects
#17
Meenasree Bukka, Poorna Jyothi Rednam, Mukty Sinha
Drug eluting balloon is a non-stent technology in which an effective homogenous delivery of anti-proliferative drug processed to the vessel wall through inflated balloon. This is done to restore luminal vascularity in order to treat atherosclerosis, in-stent restenosis and reduce risk of late thrombosis without implanting a permanent foreign object. The balloon technology relies on the concept of targeted delivery of drug which helps in rapid healing of vessel wall and prevents the proliferation of smooth muscle cell...
December 11, 2017: Biomedical Materials
https://www.readbyqxmd.com/read/29226895/a-late-complication-of-coronary-artery-perforation-during-primary-percutaneous-coronary-intervention-coronary-arteriovenous-fistula
#18
Kayıhan Karaman, Metin Karayakalı, Arif Arısoy, İlker Akar, Ataç Çelik
Coronary artery perforation (CAP) is a rare, but potentially mortal possible complication of percutaneous coronary intervention. There are several treatment options for this complication, including prolonged balloon dilatation, use of a coronary stent graft, and bypass surgery. In this case report, a 65-year-old female patient who was admitted to the catheter laboratory with a diagnosis of acute coronary syndrome, was presented. Coronary angiography revealed total occlusion in the mid segment of the right coronary artery and a drug-eluting stent was implanted under 12 atm of pressure following pre-dilatation with a perfusion balloon...
December 2017: Türk Kardiyoloji Derneği Arşivi: Türk Kardiyoloji Derneğinin Yayın Organıdır
https://www.readbyqxmd.com/read/29216997/the-state-of-the-absorb-bioresorbable%C3%A2-scaffold-consensus-from-an-expert-panel
#19
REVIEW
Sripal Bangalore, Hiram G Bezerra, David G Rizik, Ehrin J Armstrong, Bruce Samuels, Srihari S Naidu, Cindy L Grines, Malcolm T Foster, James W Choi, Barry D Bertolet, Atman P Shah, Rebecca Torguson, Surendra B Avula, John C Wang, James P Zidar, Aziz Maksoud, Arun Kalyanasundaram, Steven J Yakubov, Bassem M Chehab, Anthony J Spaedy, Srini P Potluri, Ronald P Caputo, Ashok Kondur, Robert F Merritt, Amir Kaki, Ramon Quesada, Manish A Parikh, Catalin Toma, Fadi Matar, Joseph DeGregorio, William Nicholson, Wayne Batchelor, Raghava Gollapudi, Ethan Korngold, Riyaz Sumar, George S Chrysant, Jun Li, John B Gordon, Rajesh M Dave, Guilherme F Attizzani, Tom P Stys, Osvaldo S Gigliotti, Bruce E Murphy, Stephen G Ellis, Ron Waksman
Significant progress has been made in the percutaneous coronary intervention technique from the days of balloon angioplasty to modern-day metallic drug-eluting stents (DES). Although metallic stents solve a temporary problem of acute recoil following balloon angioplasty, they leave behind a permanent problem implicated in very late events (in addition to neoatherosclerosis). BRS were developed as a potential solution to this permanent problem, but the promise of these devices has been tempered by clinical trials showing increased risk of safety outcomes, both early and late...
December 11, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/29216314/clinical-outcomes-in-patients-treated-for-coronary-in-stent-restenosis-with-drug-eluting-balloons-impact-of-high-platelet-reactivity
#20
Adrienn Tornyos, Dániel Aradi, Iván G Horváth, Attila Kónyi, Balázs Magyari, Tünde Pintér, András Vorobcsuk, Dániel Tornyos, András Komócsi
BACKGROUND: The impact of high platelet reactivity (HPR) on clinical outcomes after elective percutaneous coronary interventions (PCI) with drug-eluting balloons (DEB) due to in-stent restenosis (ISR) is unknown. OBJECTIVE: We sought to evaluate the prognostic importance of HPR together with conventional risk factors in patients treated with DEB. METHODS: Patients treated with DEB due to ISR were enrolled in a single-centre, prospective registry between October 2009 and March 2015...
2017: PloS One
keyword
keyword
113043
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"